Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Poly Medicure Ltd. Share Price
Day's Range
Low
₹1,444.00
High
₹1,478.60
Price Summary
| Previous Close | ₹1,463.20 |
|---|---|
| Day's Range | ₹1,444.00 - ₹1,478.60 |
| Open | ₹1,462.30 |
| 52 Week Range | ₹1,182.00 - ₹2,094.30 |
| Volume | 31,239 |
| Market Cap | ₹0.01 |
| Previous Close | ₹1,462.70 |
|---|---|
| Day's Range | ₹1,444.10 - ₹1,476.00 |
| Open | ₹1,468.85 |
| 52 Week Range | ₹1,184.00 - ₹2,093.95 |
| Volume | 2,272 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 457.09 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.24 |
| Price/Earning (TTM) | 47.06 |
| TTM EPS (₹) | 31.09 |
| P/E Ratio | 37.47 |
| Book Value(₹) | 4.66 |
| PAT Margin (%) | 17.00 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 14.05 |
| Trade Value ( ₹ in Lacs) | 33.23 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.24 |
| Price/Earning (TTM) | 47.06 |
| TTM EPS (₹) | 31.09 |
| P/E Ratio | 37.47 |
| Book Value(₹) | 4.66 |
| PAT Margin (%) | 17.00 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 14.05 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 3840.47 | 16018.0 |
| Expenses | N/A | N/A |
| PBT | 1170.64 | 4428.91 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 879.29 | 3313.35 |
About Poly Medicure Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Himanshu Baid |
| NSE Symbol | POLYMED |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,22,990.76 | 1,804.05 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,56,309.91 | 9,768.80 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,73,603.69 | 4,637.00 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,21,300.09 | 2,373.50 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,18,620.68 | 682.75 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,18,303.95 | 1,238.30 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,17,874.66 | 8,310.00 | 6,696.50 - 6,696.50 |
| Dr. Reddy's Laboratories Ltd. | 1,11,721.96 | 1,360.40 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,09,628.04 | 1,378.20 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,01,658.66 | 2,520.60 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Kovai Medical Center & Hospital informs about updates
Rubicon Research informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Rubicon Research has informed that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection (triggered by a product filing) of the company’s manufacturing facility located at Plot No. K30/4 & 30/5, Additional M.I.D.C., Anand Nagar, Ambernath, Maharashtra, India from Wednesday, 21 October 2026 to Thursday, 29 October 2026. This was a comprehensive GMP inspection in addition to the product application under review. Upon conclusion, a Form 483 containing 3 observations with respect to system improvement and 2 observations with respect to product application under review were issued, all 5 of which are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner. All its manufacturing as well as R&D facilities have now been inspected by the US FDA in the recent past and it has enclosed the status of all its operational facilities.
Krebs Biochem.&Inds - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 57.90 | 41.67 | 38.95 | 127.74 | 96.48 | 32.40 | 237.32 | 433.12 | -45.21 |
| Other Income | 0.37 | 0.07 | 428.57 | 1.94 | 0.19 | 921.05 | 20.26 | 7.09 | 185.75 |
| PBIDT | -18.92 | -27.86 | -32.09 | -9.09 | -48.61 | -81.30 | -34.23 | -143.21 | -76.10 |
| Interest | 19.02 | 17.33 | 9.75 | 37.83 | 33.83 | 11.82 | 70.86 | 59.14 | 19.82 |
| PBDT | -37.94 | -45.19 | -16.04 | -46.92 | -82.44 | -43.09 | -105.09 | -202.35 | -48.07 |
| Depreciation | 16.05 | 16.24 | -1.17 | 31.93 | 32.23 | -0.93 | 64.23 | 66.89 | -3.98 |
| PBT | -53.99 | -61.43 | -12.11 | -78.85 | -114.67 | -31.24 | -169.32 | -269.24 | -37.11 |
| TAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.00 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | -53.99 | -61.43 | -12.11 | -78.85 | -114.67 | -31.24 | -169.32 | -269.39 | -37.15 |
| Equity | 215.61 | 215.61 | 0.00 | 215.61 | 215.61 | 0.00 | 215.61 | 215.61 | 0.00 |
| PBIDTM(%) | -32.68 | -66.86 | -51.13 | -7.12 | -50.38 | -85.88 | -14.42 | -33.06 | -56.38 |
Lincoln Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1913.45 | 1633.64 | 17.13 | 3686.27 | 3174.31 | 16.13 | 6710.30 | 6232.30 | 7.67 |
| Other Income | 95.34 | 72.32 | 31.83 | 337.99 | 225.04 | 50.19 | 334.54 | 224.77 | 48.84 |
| PBIDT | 332.20 | 326.60 | 1.71 | 849.16 | 717.36 | 18.37 | 1311.37 | 1239.71 | 5.78 |
| Interest | 3.18 | 2.31 | 37.66 | 5.77 | 4.41 | 30.84 | 10.13 | 18.83 | -46.20 |
| PBDT | 329.02 | 324.29 | 1.46 | 843.39 | 712.95 | 18.30 | 1301.24 | 1220.88 | 6.58 |
| Depreciation | 38.84 | 36.19 | 7.32 | 77.68 | 70.96 | 9.47 | 145.00 | 128.99 | 12.41 |
| PBT | 290.18 | 288.10 | 0.72 | 765.71 | 641.99 | 19.27 | 1156.24 | 1091.89 | 5.89 |
| TAX | 85.92 | 88.26 | -2.65 | 199.11 | 165.40 | 20.38 | 277.31 | 268.42 | 3.31 |
| Deferred Tax | -8.48 | -1.25 | 578.40 | 51.18 | 34.66 | 47.66 | -0.31 | 15.15 | -102.05 |
| PAT | 204.26 | 199.84 | 2.21 | 566.60 | 476.59 | 18.89 | 878.93 | 823.47 | 6.73 |
| Equity | 200.30 | 200.30 | 0.00 | 200.30 | 200.30 | 0.00 | 200.30 | 200.30 | 0.00 |
| PBIDTM(%) | 17.36 | 19.99 | -13.16 | 23.04 | 22.60 | 1.93 | 19.54 | 19.89 | -1.76 |
Thyrocare Tech. - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 2562.50 | 2022.30 | 26.71 | 4819.10 | 3811.20 | 26.45 | 7742.70 | 6331.00 | 22.30 |
| Other Income | 29.40 | 22.80 | 28.95 | 64.50 | 62.40 | 3.37 | 133.90 | 133.40 | 0.37 |
| PBIDT | 889.80 | 711.90 | 24.99 | 1681.00 | 1316.70 | 27.67 | 2697.20 | 2003.60 | 34.62 |
| Interest | 14.80 | 6.00 | 146.67 | 27.40 | 12.20 | 124.59 | 21.80 | 26.30 | -17.11 |
| PBDT | 783.30 | 705.90 | 10.96 | 1561.90 | 1304.50 | 19.73 | 2615.70 | 1977.30 | 32.29 |
| Depreciation | 125.00 | 97.00 | 28.87 | 237.30 | 186.50 | 27.24 | 511.70 | 465.20 | 10.00 |
| PBT | 658.30 | 608.90 | 8.11 | 1324.60 | 1118.00 | 18.48 | 2104.00 | 1512.10 | 39.14 |
| TAX | 177.00 | 178.60 | -0.90 | 341.60 | 327.20 | 4.40 | 615.90 | 554.30 | 11.11 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.00 | 76.60 | -43.86 |
| PAT | 481.30 | 430.30 | 11.85 | 983.00 | 790.80 | 24.30 | 1488.10 | 957.80 | 55.37 |
| Equity | 1591.70 | 529.90 | 200.38 | 1591.70 | 529.90 | 200.38 | 1591.70 | 529.90 | 200.38 |
| PBIDTM(%) | 34.72 | 35.20 | -1.36 | 34.88 | 34.55 | 0.97 | 34.84 | 31.65 | 10.07 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Poly Medicure Ltd. is ₹1,463.20 as of 2026-10-30.
The market capitalisation of Poly Medicure Ltd. is ₹14,828.17 as of 2026-10-29.
The 1-year return of Poly Medicure Ltd. is -505.30% as of 2026-10-30.
The P/E ratio of Poly Medicure Ltd. is 37.47 as of 2026-10-30.
The 52-week high and low of Poly Medicure Ltd. are ₹2,094.30 and ₹1,182.00, respectively, as of 2026-10-30.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
